Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03989362
Recruitment Status : Recruiting
First Posted : June 18, 2019
Last Update Posted : October 15, 2019
Sponsor:
Information provided by (Responsible Party):
Jounce Therapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : July 31, 2022